ASX Announcement

Medibio Limited – 20 January 2022



Non-Renounceable Entitlement Offer Underwriting Update

Melbourne, Australia and Minneapolis, MN – 20 January 2022: Medibio Limited ("MEB" or "Medibio")(ASX: MEB)(OTCPINK: MDBIF) provides the following update on the Non-Renounceable Entitlement Offer ("Entitlement Offer") announced on 15 December 2021 and the timetable update announced on 13 January 2022.

The Company is pleased is announce that an Underwriting Agreement has been executed between the Company and CPS Capital Group Pty Ltd ("CPS" or "Underwriter") which underwrites Entitlement Offer up to \$1 million. The Company in conjunction CPS as underwriters have the ability to place the shortfall for 3 months after the close of the Entitlement Offer. The Entitlement Offer will raise up to approximately \$3.4 million (before costs).

In consideration for the underwriting CPS will receive an underwriting fee of \$20,000 and 6% fee for the underwriting amount being \$1 million, in addition, should the Underwriter place any of the shortfall it shall also receive 6% of the total of any shortfall placed.

The Company does not at this stage anticipate any changes to the timetable previously advised via the Announcement on 13 January 2022.

For Further information:

Mathew Watkins Company Secretary T: +61 3 9692 7222

- ENDS -

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Level 4, 100 Albert Road, South Melbourne, Vic 3205 Email: info@medibio.com.au | www.medibio.com.au | <a

ACN: 008 130 336